statistically significant and clinically relevant manner over the two-week study. SCORAD scores reduced by an average of 43% (day 7) and 68% (day 14) compared to baseline (Figure 2). The treatment was equally effective in both adults and children with all patients improving by day 14. Similarly, local SCORAD reduced by 42% at day 7 and 67% at day 14 compared to baseline (Table 2). Visible lesion resolution is shown in Figure 3. Notably, as early as day 3, patients reported a statistically significant decrease in PO-SCORAD (Table 3). PO-SCORAD further decreased by an average of 30% (day 7) and 50 % (day 14) with all participants reporting better scores by day 14. More specifically, skin discomfort significantly improved by day 3 in both adults and children, with itching decreased by 51%, tingling by 63% and burning by 79% at day 14 (P<0.005 vs baseline) (Table 3).
The reported improvements translated into a significantly increased QoL for all participants: 100% of children and 95% of adults reported a higher QoL on day 14 with DLQI reducing from 11.8 ± 5.4 to 4.1 ± 4.0 in adults and CDLQI from 17.3±5.4 to 6.8±5.3 in children (P<0.001 vs baseline) (Figure 4,Table 4).
Participants reported a good cosmetic acceptability. After just 7 days, 98% of participants reported that the study product left a protective film on the skin and the skin felt comfortable. By day 14, all patients agreed that the study product was easy to apply with 91% wanting to continue using it.
The reported improvements translated into a significantly increased QoL for all participants: 100% of children and 95% of adults reported a higher QoL on day 14 with DLQI reducing from 11.8 ± 5.4 to 4.1 ± 4.0 in adults and CDLQI from 17.3±5.4 to 6.8±5.3 in children (P<0.001 vs baseline) (Figure 4,Table 4).
Participants reported a good cosmetic acceptability. After just 7 days, 98% of participants reported that the study product left a protective film on the skin and the skin felt comfortable. By day 14, all patients agreed that the study product was easy to apply with 91% wanting to continue using it.
DISCUSSION
For the first time, our study demonstrates the efficacy of an anti-S. aureus product in children and adults with AD. With Endobioma monotherapy, both clinicians and participants including children reported significantly improved skin sensitivity, PO-SCORAD and overall QoL. A recent Cochrane review30 analyzed studies aiming to reduce S. aureus in AD patients and failed to correlate anti-staphylococcal intervention with improvement in symptoms and QoL especially in children. However, our results suggest that a precision ingredient like Endobioma alone could be a potential alternative to traditional
